Penn.-based commercial payer using accelerated approval to justify coverage denials of non-oncology products for 18 months

Plus: BridgeBio’s Attruby approved for ATTR-CM, PTC’s gene therapy for AADC deficiency, and Gilead withdrew Trodelvy for urothelial cancer

Biotech retains upside in licensing agreement for oral therapy derived from same splicing platform as SMA drug

Biotech expects to sell voucher after winning gene therapy’s approval for AADC deficiency based on 13-patient study

Upcoming decisions include BridgeBio’s 

Second neurology gene therapy deal for partners focused on Parkinson’s disease

Plus: vaccines stand out for Sanofi, and updates from Outlook, PTC, Y-mAbs, Ascletis, Agios and more

Plus Section 32 leads BigHat’s $75M round; PTC gains first global approval of brain-infused gene therapy; and more

And how they’re shifting the development landscape